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Abstract Early detection of prostate cancer is associ-
ated with the diagnosis of a considerable proportion of
cancers that are indolent, and that will hardly ever
become symptomatic during lifetime. Such overdiagno-
sis should be avoided in all forms of screening because
of potential adverse psychological and somatic side
eVects. The main threat of overdiagnosis is overtreat-
ment of indolent disease. Men with prostate cancer
that is likely to be indolent may be oVered active sur-
veillance. Evaluation of active surveillance studies and
validation of new biological parameters for risk assess-
ment are expected.
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Introduction
What is the rationale for screening?
Screening for diseases, especially cancer, has become
part of modern medicine. Screening for breast, cervi-
cal and colorectal cancer is already normal practice in
some countries, and will probably become routine in
other countries in the future. Screening for prostate,
melanoma and lung cancer are subject to ongoing
studies [1–5]. The rationale behind screening is sim-
ple: to detect cancers at an early stage, when they are
still curable. Screening is currently performed using
one of the three methods: mass screening (i.e. large
scale screening of an entire population), selective
screening (i.e. screening of high-risk populations) or
opportunistic screening (e.g. incorporated as part of a
medical consultation). Diagnostic testing diVers from
screening because it attempts to identify the disease
in the presence of symptoms, while screening is
oVered to symptom-free individuals.
In any population screened for cancer, four basic
groups of patients exist: those diagnosed with cancer
who would not have developed cancer symptoms dur-
ing their lifetime (overdiagnosis); those diagnosed
with cancer at an early stage that might otherwise
have led to symptoms and/or the need for more
aggressive curative treatment; those diagnosed with
cancer at a curable stage with aggressive disease that
might otherwise have progressed to metastatic dis-
ease at the time of diagnosis; and those whose cancer
is diagnosed by screening at the same stage as it
would have been diagnosed through clinical routines,
and that involves cancers that are too late for curative
therapy. Ideally, screening should reduce the number
of patients in the fourth group (that cannot be cured),
and increase those in the second and third group. The
window of opportunity for decreasing cancer-mortal-
ity by screening for cancer lies with the second and
third group. Randomized clinical trials, considered
the gold standard for the evaluation of a screening
test, have to show how sizeable the window of oppor-
tunity is. The diVerence between the Wrst group and
the second is however not always clear at the time of
initial diagnosis. Any screening procedure carries a
risk of overdiagnosis and overtreatment, which
should be balanced against the beneWts for those in
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which the cancers are diagnosed at a curative stage.
Whether this balance is justiWable depends on more
than mortality diVerences of randomized study
groups only, but also on quality of life issues mea-
sured against the cultural background of the popula-
tion studied.
Incidence
Does screening inXuence prostate cancer incidence?
Since the potential value of PSA for the early detec-
tion of prostate cancer was described in the early
1990s, both prostate cancer incidence and mortality
rates have changed profoundly [6]. Between 1989 and
2003, for example, the age-standardized incidence
rate of prostate cancer increased by 48.4% in The
Netherlands (reaching an incidence of 93.2 cases per
100,000 men). Based on rates from 2001 to 2003,
17.1% of U.S. men born today will be diagnosed with
cancer of the prostate at some time during their
lifetime [http://www.cancer.gov] . It is now the  most
frequently diagnosed non-cutaneous cancer, with
225,000 new cases reported each year in Europe alone
[7]. This increase of incidence suggests that this is due
to the detection of cancers in the Wrst three groups
described above. This is supported by the reports on
autopsy studies. These autopsy studies have revealed
that histologic prostate cancer occurs in an even
larger proportion of men compared to the screening
incidence: up to 55% of men in their Wfties, and 64%
of men in their seventies have prostate cancer diag-
nosed at autopsy, while only 5–10% are detectable in
a screening setting during life [8].
A number of inXuences might have contributed to
the increase of cancer diagnosis over the last
decades, apart from the structured screening studies
that have been initiated at various places. First, the
PSA thresholds for biopsy appears to have been
reduced gradually in some areas of the world due to
the detection of signiWcant cancers in the low PSA
range [9]. Most guidelines, however, still mention the
traditional cut-oV of 4 ng/ml as an indication for
biopsy. Secondly, an increase in the number of core
samples per biopsy have been advocated, based on
the observation that more cancers are diagnosed
when more biopsies are taken. Thirdly, awareness of
prostate cancer within the general population has
increased stimulated by the information obtained
predominantly from the urologic profession [10]. If
these current trends continue, the number of living
men diagnosed with prostate cancer will increase
even further [11].
Mortality
What happens to prostate cancer mortality by screening 
and detecting indolent tumors?
Despite this rising incidence, the age-standardized pros-
tate cancer mortality rate has decreased in many coun-
tries around the world with or without early detection
programs. In The Netherlands, for example, rates fell
by 11% between 1989 and 2003, to 28.4 deaths per
100,000 men or 2,349 in total [http://www.cancer.gov]. It
is however unclear whether the stage and grade migra-
tion observed in screening studies results in a reduction
in the mortality, although case-control studies with con-
Xicting results are available [12–14]. A decrease of mor-
tality shown in randomized studies would form a strong
argument in favor of population screening.
Screening results in the more frequent detection of
small volume, low grade and organ conWned prostate
cancers, which are diagnosed earlier in their course [6,
15]. Many of these tumors have the histological charac-
teristic of autopsy tumors, that is, tumors that have not
become symptomatic during life [16]. They have been
called indolent or clinically insigniWcant cancers. Vari-
ous deWnitions of clinically insigniWcant tumors have
been designed based on the characteristics of the
autopsy studies, of which the Epstein deWnition is
widely known [17]. Detecting such tumors will increase
the detection frequency of cancer, but it is unlikely that
they will inXuence the prostate cancer speciWc mortal-
ity, as they do not alter the course of life.
Early diagnosis
Screen detected tumors are diagnosed more early
Screen detected tumors are not only diagnosed more
often, but can be expected more early during their natural
course. Lead-time is deWned as the time period from
detection by a screening procedure to the time of diagno-
sis in absence of screening due to symptoms. If the patient
dies during the lead-time period of the tumor, the lead-
time is indeWnite and therefore equal to overdiagnosis.
Early detection by PSA advances prostate cancer
diagnosis in time (i.e. lead time) [18]. For men aged 55–
75 years lead time amounts to 12.3 years in a screening
setting [19]. The lead-time is likely to be shorter for
aggressive cancers and longer for indolent ones. Early
detection also causes a signiWcant stage shift towards
more locally conWned and less aggressive cancers [20].
The long lead-time, stage reduction and natural history
data cited above indicate that for properly selected
cases there is a long ‘time-window’ during which obser-World J Urol (2007) 25:3–9 5
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vation is safe without losing the opportunity for cure.
This is supported by evidence from nomograms, prog-
nostic tables, and by the only available randomized
study of observation against radical prostatectomy [21].
The impact of overdiagnosis and unnecessary treat-
ment and of its side eVects on patient health is also
unclear; however, application of a mathematical model
(the Miscan model) on data from the ERSPC has
shown that, in an annual screening program for men
aged 55–67 years, 56% of diagnosed cases would con-
stitute instances of overdiagnosis [22]. If this estimate
proves to be realistic (as it appears to be the case),
nationwide screening programs may not be acceptable
using the present screening regimens, even if beneWts
in terms of mortality reduction were shown. Research
aimed at the development of more selective screening
tools is therefore very important.
The natural course of screen-detected cancers
The current knowledge of the natural history of prostate
cancer is mainly based on clinically detected cases, diag-
nosed by disease-related symptoms, or coincidentally at
the time of unrelated symptoms of the urinary tract.
Natural history data on screen-detected cases of pros-
tate cancer will be created as a result of the large ongo-
ing screening studies worldwide in which tumors might
have been treated without invasive therapy [1]. Most
studies show histological and cytological grade to be the
most important prognostic variable [23, 24]. There is a
steep decline in the 5-, 10- and 15-year cancer-speciWc
survival with increasing grade. Most prostate cancer
cases diagnosed with present diagnostic techniques fall
into the moderately diVerentiated group (grade 2, Glea-
son 6), of which the cancer-speciWc 10–15-year mortality
is 18–30%. This is even lower in the group of prostate
cancers diagnosed with grade 1 and 2 or Gleason 4–6,
and there are subgroups of patients who are not at risk
of dying from prostate cancer even within 15 years.
Overall mortality is then determined by comorbidity.
The majority of these men are currently treated for
their prostatic disease with invasive procedures, which
might not be needed. Adequate prediction of the out-
come of comorbid diseases would be of great support in
predicting the outcome of the prostate cancer patient.
Overdiagnosis
Overdiagnosis and overtreatment, what does it mean?
During recent years, increased interest has risen to the
possibility that increased detection of prostate cancer
may lead to the diagnosis of cancers that rather should
not have been diagnosed, and certainly should not
have been treated, as their detection and subsequent
treatment is unlikely to beneWt patients, or even might
harm them. Related to this, the terms ‘overdiagnosis’
and ‘overtreatment’ are being used. So, when is pros-
tate cancer overdiagnosed?
By using the clinical deWnition of overdiagnosis, that
is diagnosing tumors that would otherwise remain clin-
ically unrecognized until the individual died from other
causes, it is clear that this deWnition can only be applied
in retrospect in the evaluation of studies. There are
currently no clinical or biological parameters that can
identify such tumors 100% adequately at the time of
diagnosis. By studying the natural course of prostate
cancer, and comparing autopsy results with Wndings
from screened populations, clinical and histological
parameters can be identiWed that predict indolent
tumors best. Those indolent tumors are likely to be
only a subset of the tumors that are overdiagnosed in
retrospect.
Overdiagnosis is predominantly being associated
with early detection or screening programs. Overdiag-
nosis appears to be especially harmful when it results in
invasive treatment of the tumors that would unlikely to
be harmful. This is called overtreatment.
Overdiagnosis occurs when screening detects small
tumors that would otherwise remain clinically unrecog-
nized until the individual dies from other causes. Such
tumors are predominantly found in the low PSA
ranges. Unfortunately, an unknown number of biologi-
cally more aggressive cancers may hide between the
larger number of detectable tumors with favorable
stages. Though some of the aggressive tumors can be
diagnosed by adverse histological criteria such as high
Gleason score in the biopsy, some of these features
might be missed due to the heterogeneity of prostate
cancers and their representation in the biopsy sam-
pling. This might justify the amount of overtreatment
that has been practiced in various areas of the world.
Overtreatment is thus deWned as unnecessary invasive
treatment with respect to the outcome of the natural
course of the tumor in combination with its host.
One can wonder what number needed-to-treat to
prevent one prostate cancer death we are prepared to
accept. Based on the Swedish randomized trial of radi-
cal prostatectomy versus watchful waiting [22], the
Connecticut observation series [15], and the Toronto
active surveillance experience [25], a number needed
to treat analysis of the beneWt of radical treatment of
all newly diagnosed favorable-risk prostate cancer
patients, compared with a strategy of active surveil-
lance with selective delayed intervention, has been6 World J Urol (2007) 25:3–9
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presented by Klotz [25]. This suggested that approxi-
mately 73 patients will require radical treatment for
each prostate cancer death averted. This translates into
a 3- to 4-week survival beneWt, unadjusted for quality
of life. If any, the number of life-years gained will be
small, because of the fact that prostate cancer is a dis-
ease of old age. This should be contrasted to the side-
eVects of all applied treatments. As a minimum, the
number of men needed to treat should be higher than
the number of men dying from intervention related
causes.
Informed decision making, reduction of unnecessary 
prostate biopsies
The increasing number of diagnostic procedures and
subsequently of prostate cancer diagnosis in various
areas of the world is partly fed by an increased aware-
ness of prostate cancer and the anxiety raised of suVer-
ing from a devastating disease at the end of life. Men
should ask themselves if they are at speciWc risk for
having prostate cancer, and if they want to follow the
step wise procedure of PSA testing, urologic investiga-
tions, prostate biopsies, and potential treatment. Bal-
anced information regarding this procedure and its
consequences should be oVered to every man consider-
ing prostate testing. Validated information (that is:
well understandable text that delivers the information
that is required) has been made available in several
countries around the world, and it has been shown that
such information reduces the number of men who
initially wanted to be screened.
Based on population data it is possible to provide
risk assessments for every step of the screening proce-
dure. Such assessments produce an individual risk cal-
culation based on relevant risk parameters. This might
support patients and doctors in their decision to fol-
low or refrain from further steps, dependent on their
interpretation of the risk calculated. At the time of
cancer diagnosis, it may provide information on the
risk of the presence of an indolent tumor, as discussed
above.
Current risk calculators have incorporated family
history, age, micturition complaints, PSA, DRE,
TRUS results, and histologic features of the prostate
biopsies into their assessment. With an increasing num-
ber of relevant parameters, the level of predictive accu-
racy is enhanced. It is likely that new parameters might
be added once tested in population-based bioreposito-
ries. Candidate parameters therefore obviously are
serum and urine markers for the early diagnostic steps,
and histologic markers at the time that biopsies have
been taken.
Much interest has been given to the increase of spec-
iWcity of the biopsy procedure in the general popula-
tion with serum markers like PSA isoforms and
kallekreins in order to diminish the number of false
negative biopsies [26, 27]. Enhancing speciWcity always
resulted in a reduction of sensitivity of prostate can-
cers. As we have seen based on autopsy incidence, the
number of potentially detectable tumors is manifold
the number of currently diagnosed cancers. It is there-
fore not the absolute number, but the number of clini-
cally relevant cancers that is of interest [28]. The PSA
isoforms and kallekreins should therefore ideally be
related to the characteristics of the cancers detected.
Screening eYciency
A small number of studies already have provided evi-
dence that supports strategies to reduce the number of
screens in the general population. Such strategies will
inevitably lead to the reduction of overdiagnosis of
prostate cancer.
Information obtained from population based screen-
ing studies illustrates that the absolute value of serum
PSA is related to the proportion of detectable carcino-
mas in subsequent screening rounds. Data from the
ERSPC as well as from the PLCO [29, 30] showed that
men with a PSA less than 1 ng/ml did not develop inva-
sive cancer over the time period of more than 5 years
of repeated check-ups. In the Rotterdam site of the
ERSPC, 1703 men with an initial PSA of less than 1 ng/
ml men were followed during two consecutive 4 year
screening rounds. Eighty percent of men attended the
second screening round, and 77% the third round. In
total, only 8 cancers were found in 47 prostate biopsies
on the indication of PSA of >3 ng/ml. In the PLCO
screening, every 5 years for baseline PSA less than
1 ng/ml and every 2 years for PSA 1–2 ng/ml could
result in a 50% reduction in PSA tests and in less than
1.5% of men missing earlier positive screens.
In men who were enrolled onto a cardiovascular
study in Sweden, 21,277 men aged <50 years old were
assessed over a period of more than 20 years starting
between 1974 and 1986. Two decades later, 498 (2.3%)
were eventually diagnosed with prostate cancer (out-
side a structured screening procedure). In retrospect,
the level of serum kallikreins (hK2, total PSA, and free
PSA) at baseline and thereafter were strongly associ-
ated with emerging prostate cancer. This supports the
idea of risk stratiWcation for screening on prostate can-
cer in an early age, that is during the fourth decade of
life. Men at low risk may refrain from frequent serum
testing for long periods of time based on their individ-
ual risk assessment that incorporates the informationWorld J Urol (2007) 25:3–9 7
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obtained from currently available and newly validated
parameters.
Overtreatment
Side eVects of treatment are substantial
Treatment for prostate cancer may involve surgery,
external beam radiation therapy, brachytherapy, high
intensity focused ultrasound (HIFU), watchful waiting,
active surveillance, chemotherapy, cryosurgery, hor-
monal therapy, or combinations. The most frequently
applied treatments for organ conWned prostate cancer
are radical prostatectomy, external beam radiotherapy
and brachytherapy.
Although, severe or life-threatening complications
with radical prostatectomy are rare, the adverse eVects
of greatest concern are damage to the urinary sphincter
and erectile nerves (nervi erigenti), resulting in urinary
incontinence and impotence, respectively. Complete
incontinence is uncommon after radical prostatectomy,
although a signiWcant number of men experience some
degree of stress-urinary incontinence [31–33]. In the
Prostate Cancer Outcomes Study, a population-based
study of 1,291 men who underwent radical prostatec-
tomy for localized prostate cancer and were followed
for 2 years, 1.6% reported no urinary control at
24 months following surgery (compared with 0.7% at
baseline prior to surgery), while 7 and 42% reported
frequent and occasional leakage, respectively (com-
pared with 2 and 9% at baseline) [32]. Age had an
impact on the degree of incontinence; 14% of men
aged between 75 and 79 years experienced the highest
level of incontinence compared with 0.7–4% of youn-
ger men. In the Prostate Cancer Outcomes Study, 42%
of men reported that sexual performance was a moder-
ate to large problem at 24 months (compared with 18%
at baseline); 60% were not able to have erections Wrm
enough for sexual intercourse (compared with 16% at
baseline) [32]. At 24 months postoperatively, men over
the age of 60 were more likely to be impotent than
younger men (78–85 vs. 61%, respectively).
Complications after external beam radiotherapy
include bladder irritation (urgency, pain, frequency) in
up to 5% of men, and impotence in 40–50% [34]. In
contrast to surgery, these complications tend to
increase over time. The reported incidence of radiation
proctitis ranges from 2 to 39%, depending upon the
deWnition used, and the dose Weld, and technique of
radiotherapy. Prostate inXammation and swelling can
occur acutely following brachytherapy, suggesting that
men with signiWcant urinary symptoms or a large
prostate are not good candidates. Urinary retention
can be severe enough to require self-catheterization;
transurethral resection to improve micturition is con-
traindicated until a substantial portion of the radioac-
tivity (usually Wve half-lives) has dissipated because of
the risk of incontinence and radiation risks to the sur-
geon and pathologist. Later complications include irri-
tative voiding symptoms, urinary retention, rectal
urgency, bowel frequency, rectal bleeding or ulcera-
tion, and prostatorectal Wstulas [35–37]. The incidence
of erectile dysfunction ranges from 14 to 52%, depend-
ing on whether it is physician- or patient-reported.
It is obvious that invasive treatment may inXuence
the quality of life of men with prostate cancer and their
families substantially. But so does a potential threat of
prostate cancer that is not actively treated or not even
diagnosed yet. It is unlikely that quality of life studies
will be able to indicate the best balance between these
points of view for management decisions on an individ-
ual patient level.
Active surveillance as alternative to invasive treatment
Because not all cancers diagnosed require treatment,
one of the major challenges for the future is to deter-
mine which diagnosed cancers should be treated, and
which can be managed by active surveillance. Active
Surveillance manages selected men with prostate can-
cer expectantly with curative intent. This means men
are carefully selected and subsequently actively
observed in order to have the possibility to oVer them
deferred curative treatment once the tumor seems to
progress. Active surveillance should be clearly diVer-
entiated from watchful waiting. Watchful waiting
entails a strategy for all men who are managed expec-
tantly, whereas active surveillance focuses on men for
whom therapy is delayed until the tumor becomes pro-
gressive and curative treatment can be oVered. This
oVers an attitude of active control over the cancer diag-
nosed for patients and their doctors. The stage migra-
tion that screening provides has resulted in an over-
representation of low-risk cancers. Therefore, studies
which validate monitoring algorithms in active surveil-
lance regimens are ongoing [38].
Risk stratiWcation for indolent disease
Over the last decade, a number of nomograms have
been composed to predict the presence of an indolent
cancer [39, 40]. The identiWcation of indolent cancers
was strongly based on histologic information of pros-
tate biopsies, and power of Gleason score as a predic-
tive parameter for aggressiveness of prostate cancer8 World J Urol (2007) 25:3–9
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was unsurpassed. As a single serum parameter at the
time of diagnosis, the level of PSA contributed most to
prognosis.
These nomograms were based on extensive clinical
series. A new nomogram recently appeared based on
information obtained from a screening series of the
general population [41]. Screening series diVer from
clinical studies, as the incidence of indolent cancer is
almost 50% compared to maximal 20% in multicentred
clinical series. With the use of the nomogram, at a 70%
probability cut-oV, at least 69% of all indolent cancers
would be diagnosed as such, and be treated with active
surveillance.
Conclusions
It is still too early to say whether population-based
prostate cancer screening is a useful tool with regard to
cancer mortality. We must wait until the results of
ongoing prostate cancer screening trials are available.
Until then, opportunistic screening should not be
encouraged and those men who do want a PSA test
should participate in carefully designed, balanced
information program. Even if PSA screening is found
to reduce prostate-cancer-speciWc mortality, levels of
overdiagnosis may remain unacceptable for popula-
tion-based screening.
To reduce overdiagnosis in a screening setting,
markers are needed that reduce the risk on a positive
prostate biopsy, increasing the speciWcity of this proce-
dure. Men from the age of forty, as well as their advis-
ing doctors, need instruments to reduce their doubts
and anxiety of the potential presence of a prostate can-
cer. This, together with balanced information about the
beneWts and risks of the individual outcome of screen-
ing procedures, might induce a more selective and
step-wise screening action. Risk assessment, incorpo-
rating the main determinants known for the presence
of prostate cancer from the age of 50, such as age, fam-
ily history, and micturition complaints, should form the
base of an individual screening approach. Objective
values of serum markers might enhance the accuracy of
such of risk predictors.
Various eVorts are performed to Wnd new markers in
the proteome and genome of blood and urine. Based
on large and longitudinal serum collections of men
diagnosed with prostate cancer in screening settings,
the EC-sponsored P-MARK consortium evaluates can-
didate markers as prognostic tools [42].
Until alternative screening tools are found, PSA will
continue to be used, and overdiagnosis will remain an
unavoidable drawback of prostate cancer screening.
The current challenge is to ensure that in the still
growing numbers of men diagnosed with prostate can-
cer world-wide, overdiagnosis does not result in over-
treatment. To this end, research eVorts presently focus
on clarifying which cancers can be managed through
active surveillance.
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